Background--Patients presenting to hospitals during non-weekday hours experience worse outcomes, often attributed to reduced staffing. The American Heart Association International Stroke Conference (ISC) is well attended by stroke clinicians. We sought to determine whether patients with acute ischemic stroke (AIS) admitted during the ISC receive less guideline-adherent care and experience worse outcomes.
M ultiple studies have reported that patients who present to a hospital during a weeknight or weekend receive suboptimal care and experience worse outcomes, possibly attributable to reduced staffing during these periods. [1] [2] [3] Similar challenges may exist when physicians attend large disease-specific scientific meetings during which staffing may be reduced and clinicians who stay behind may have less expertise in caring for patients with the relevant disease. A prior study of high-risk patients with heart failure and cardiac arrest who presented to teaching hospitals during the time of national cardiology meetings had lower 30-day mortality, although patients with acute myocardial infarct were less likely to receive a percutaneous coronary intervention. 4 It remains unclear how major scientific meetings affect the care of patients with acute ischemic stroke (AIS). The American Heart Association/American Stroke Association International Stroke Conference (ISC) is the largest conference of its kind in the world and attracts physicians, nurses, and coordinators focused on stroke care and research. Get With The Guidelines (GWTG)-Stroke is a voluntary national registry and quality improvement initiative that captures a substantial percentage of stroke admissions in the United States and provides a unique opportunity to assess the impact of this annual meeting on the care of patients with AIS. We hypothesized that patients with AIS admitted during the ISC would receive intravenous tissue plasminogen activator (tPA) at the same rate and that they would have similar overall quality-of-care and clinical outcomes as patients admitted at other times.
Methods
Several previous publications provide detailed descriptions of the GWTG-Stroke program. 5 Briefly, GWTG-Stroke is a national stroke quality improvement program available to any US hospital since April 2003. The web-based patient management tool (Outcome; A Quintiles Company, Cambridge, MA) uploads abstracted deidentified patient data into the GWTG-Stroke database. All institutions participating in GWTG-Stroke comply with local regulatory and privacy guidelines, and institutional review board approval is obtained, if required. Because data are used primarily for quality improvement at each site, they are granted a waiver of informed consent under the Common Rule. The Duke Clinical Research Institute (Durham, NC) serves as the data analysis center and maintains institutional review board approval to analyze aggregate deidentified data for research purposes. Because data were collected for clinical care and quality improvement rather than primarily for research, the American Heart Association (the steward of the data according to contracts between the American Heart Association and participating hospitals) cannot provide the data, statistical analysis code, or other study materials to other researchers.
Study Population
We identified all patients admitted with a diagnosis of AIS over a 5-week period, including the 2 weeks before the ISC, the ISC week, and the 2 weeks after the ISC each year from 2009 to 2015 (see Table S1 for specific dates used). We excluded patients given experimental therapy, those transferred to a GWTG-Stroke hospital, those with stroke while already admitted to the hospital, those with missing time of arrival to the emergency department, those missing time of last known well, those missing intravenous tPA information, and those missing discharge status.
Statistical Analyses
To ensure that there were no meaningful differences for the time periods before and after the ISC, we first assessed the use of tPA, as well as patient and hospital characteristics, for admissions during the 2 weeks before the ISC compared with the 2 weeks after the ISC. 
Results
There were 69 738 patients with AIS included in the analysis. The mean age was 72 years, 52% were women, and 29% were nonwhite. Intravenous tPA was given to 11 437 patients
Clinical Perspective
What Is New?
• Clinical quality care metrics and outcomes for patients admitted with acute ischemic stroke do not change during the time of the International Stroke Conference.
What Are the Clinical Implications?
• These findings are reassuring for sites that participate in the Get With The Guidelines-Stroke quality improvement program.
• It is unknown whether patients with stroke admitted to hospitals that do not participate in Get With The Guidelines are similarly unaffected by the International Stroke Conference. Comparing ISC with non-ISC weeks, there was no difference between the average weekly number of acute stroke admissions during ISC weeks compared with non-ISC weeks (1984 versus 1997; P=0.95). Similarly, there were no differences for patient and hospital characteristics between ISC and non-ISC time periods ( Table 2 ). As shown in Table 3 , there were no differences in 14 quality-of-care metrics and 5 clinical outcomes between ISC and non-ISC weeks, including percentage of patients who received intravenous tPA (16.4% versus 16.4%; P=0.94), symptomatic intracerebral hemorrhage after tPA (4.0% versus 4.3%; P=0.66), or discharge to home (48.2% versus 48.4%; P=0.68). The percentage of patients who arrived within 2 hours and were treated with intravenous tPA by 3 hours and those who arrived within 3.5 hours and were treated with intravenous tPA by 4.5 hours were similar before, during, and after the ISC in each year (Figure) . After adjusting for potential confounders, patients with acute stroke who presented within 2 hours of onset had no difference in the likelihood of receiving intravenous tPA within 3 hours (adjusted odds ratio, 0.89; 95% confidence interval, 0.77-1.03; P=0.13). Similarly, there was no difference in the likelihood of receiving intravenous tPA within 60 minutes of arrival (adjusted odds ratio, 0.92; 95% confidence interval, 0.83-1.02; P=0.13). There was no evidence of interaction by teaching hospital (P=0.99 for arrive by 2 and treat by 3 hours, and P=0.29 for door-to-needle time of <60 minutes) or hospital size (P=0.91 for arrive by 2 and treat by 3 hours, and P=0.68 for door-to-needle time of <60 minutes).
Discussion
This study identified no degradation in the quality of care given to patients with AIS admitted during the week of a major conference on cerebrovascular disease. Patients were just as likely to receive intravenous tPA, with a similar door-to-needle time and with similar adherence to guideline-based quality measures during the ISC as at other times. Clinically important outcomes, including symptomatic intracerebral hemorrhage rate after intravenous tPA, ambulatory status at discharge, and discharge to home, were unchanged during the conference. Finally, there was no evidence of an interaction The GWTG-Stroke registry is one of the largest available data sets of hospitalized patients with stroke in the world and represents a mix of academic and nonacademic hospitals of varying sizes from all the regions of the United States. There are almost 2000 hospitals currently active in the program, representing %40% of all hospitals in the United States and %75% of incident stroke cases. It is representative of the Medicare fee-for-service population with ischemic stroke, and the specificity of included patients and data accuracy have been demonstrated to be high. 6, 7 However, there are notable limitations to this study. Hospitals that participate in GWTG have inherently demonstrated an interest in improving stroke care. GWTG-Stroke provides protocols, templates, and clinical tools that are designed to standardize care with guidelineadherent practices. Furthermore, participating hospitals submit data and can track their performance on quality care measures, with public recognition awards given to hospitals that meet established thresholds. Thus, it is likely that these hospital practices become established as routine and are not dependent on individual clinicians' practices. As evidence of the impact of GWTG-Stroke participation, a quality improvement initiative undertaken to disseminate practices associated with faster intravenous tPA treatment resulted in improved timeliness of tPA administration, lower in-hospital mortality and intracranial hemorrhage rates, and an increased percentage of patients discharged home. 8 Similarly, a recent multicenter, cluster-randomized clinical trial among 40 public hospitals in China demonstrated that instituting a quality improvement intervention, including a clinical pathway, care protocols, quality coordinator oversight, and performance measure monitoring and feedback, resulted in improvement in performance measures of patient care and a reduction in recurrent vascular events up to 1 year after discharge. 9 However, given that this analysis was limited to hospitals participating in GWTG-Stroke, it is not clear whether these results would generalize to hospitals that do not participate in the program. A final limitation that deserves mention is the fact that the data from GWTG-Stroke are dependent on the accuracy and completeness of clinical documentation. More important, there was no decrease in the number of strokes reported during the week of the ISC and no difference in missingness in key variables, suggesting that selective documentation was not occurring during the time of the conference.
In conclusion, the care and outcomes of patients with acute stroke at hospitals participating in GWTG-Stroke do not differ during the time of a major conference on cerebrovascular disease compared with other times.
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